L Hayley Burgess
Overview
Explore the profile of L Hayley Burgess including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
62
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Burgess L, Kramer J, Olp J
HCA Healthc J Med
. 2023 Jul;
4(2):73-75.
PMID: 37424980
Description Medications are the mainstay of treatment for many disorders and diseases. Our guest editorial board is proud to highlight the complexity of medication management and the talented pharmacists dedicated...
12.
Warren C, Kramer J, Burgess L
HCA Healthc J Med
. 2023 Jul;
4(2):167-180.
PMID: 37424970
Background: Medication errors continue to be a leading cause of medical errors. In the United States alone, 7000 to 9000 people die annually due to a medication error, and many...
13.
Zambrano S, Patel R, Burgess L, Heath K
HCA Healthc J Med
. 2023 Jul;
2(4):239-242.
PMID: 37424850
Description Health-system pharmacy leaders are tasked with determining key staffing decisions based on evolving patient care needs and present-day staffing capacity. A systematic approach to evaluate patient care needs, current...
14.
Sands K, Wenzel R, McLean L, Korwek K, Roach J, Miller K, et al.
Int J Infect Dis
. 2020 Dec;
104:34-40.
PMID: 33359949
Background: The use of hydroxychloroquine (HCQ), with or without concurrent administration of azithromycin (AZM), for treatment of COVID-19 has received considerable attention. The purpose of this study was to determine...
15.
Sands K, Wenzel R, McLean L, Korwek K, Roach J, Poland R, et al.
Infect Control Hosp Epidemiol
. 2020 Oct;
42(2):228-229.
PMID: 33040751
Coronavirus disease 2019 (COVID-19) has migrated to regions that were initially spared, and it is likely that different populations are currently at risk for illness. Herein, we present our observations...
16.
Burgess L, Cooper M, Wiggins E, Miller K, Murray E, Harris S, et al.
J Pharm Pract
. 2020 Oct;
35(2):184-189.
PMID: 33016180
As the COVID-19 pandemic swept through the United States, our heath-system mobilized clinical pharmacy services to address critical clinical medication management needs. Reinforcing recommended medication management strategies for clinical pharmacists...
17.
Sands K, Wenzel R, McLean L, Korwek K, Roach J, Miller K, et al.
Infect Control Hosp Epidemiol
. 2020 Sep;
42(4):399-405.
PMID: 32928319
Objective: To determine risk factors for mortality among COVID-19 patients admitted to a system of community hospitals in the United States. Design: Retrospective analysis of patient data collected from the...
18.
Murray K, Burgess L, Miller K
Am J Health Syst Pharm
. 2020 May;
77(16):1275-1276.
PMID: 32406905
No abstract available.
19.
ONeal F, Kramer J, Cooper M, Septimus E, Sharma S, Burgess L
Am J Health Syst Pharm
. 2019 Oct;
76(21):1753-1761.
PMID: 31612925
Purpose: To assess antibiotic selection, administration, and prescribing practices in emergency departments across a large hospital system using evidence-based practices and susceptibility patterns. Methods: This retrospective data review was conducted...
20.
Daniel J, Kramer J, Burgess L
J Patient Saf
. 2019 May;
17(4):e350-e354.
PMID: 31045622
Objective: The aim of the study was to determine the effect on occurrence of oral anticoagulant adverse drug events (ADEs) after implementation of a real-time clinical surveillance tool in a...